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Abstract: Objective: PTH increases ionic calcium concentration in the serum, acting primarily on bone and kidney cells 
through the type 1 PTH receptor. Interestingly, PTH stimulates bone formation when administrated intermittently   
but causes severe bone loss with continuous administration. Daily injections of PTH are used as the most promising  
anabolic agent in the treatment of severe osteoporosis. Elevated PTH is reported an independent risk factor for left   
ventricle hypertrophy.  
Design: in rats we investigated the effect of intermittent and continuous administration of PTH on blood pressure, heart 
rate and development of cardiac hypertrophy and fibrosis.  
Results: We did not find PTH to induce heart hypertrophy. In contrast, continuous administration of PTH the mRNA level 
of a hypertrophic marker gene, atrial natriuretic peptide. When comparing the effect of continuously versus injected PTH 
collagen 1 mRNA was significantly higher in continuously treated animals.  
Conclusion: our data demonstrated a decrease in heart rate upon continuous administration of PTH in rats. No changes in 
blood pressure were observed. Moreover, neither intermittent nor continuous administration of PTH induced ventricular 
hypertrophy. But continuous PTH induced a marker of collagen 1. Thus, these data did not reveal any negative effects of 
the injection of PTH on the cardiovascular system. 
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1. INTRODUCTION 
  Parathyroid hormone (PTH) is a peptide hormone se-
creted by the parathyroid glands. PTH is the most important 
endocrine regulator of short-term calcium homeostasis. Con-
centration of ionic calcium (Ca
2+) in extracellular fluid is 
sensed by the calcium-sensing receptor residing on the sur-
face of the cell membrane of the parathyroid cells. A de-
crease in Ca
2+ induces a release of PTH, whereas an increase 
in Ca
2+ level has an inhibitory effect on the PTH secretion 
through the calcium-sensing receptor [1-3]. In turn, PTH 
increases calcium concentration primarily by acting on bone 
and kidney cells through the type 1 PTH receptor (PTH1R), 
causing the linning cells of the bones to release calcium into 
the blood and enhancing the amount of calcium reabsorped 
along the nephron. 
  PTH (1-34) is a promising anabolic agent to date in   
the treatment of osteoporosis [4]. This is due to direct stimu-
lation of bone formation. PTH injections improve bone   
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qualities, increase bone mass and prevent osteoporotic frac-
tures. However, the effects of PTH are paradoxical as PTH 
stimulates bone formation when injected once daily but 
causes severe bone loss when continuously infused or se-
creted by the parathyroid glands as in hyperparathyroidism 
[5]. 
  In addition to the major PTH target organs, the kidney 
and bone, PTH also has effects on other tissues, including 
heart and blood vessels [6]. PTH1R is widely expressed 
throughout the cardiovascular system, including heart [7]. 
Moreover, mice lacking the PTH1R die prenatally with mas-
sive cardiac necrosis, indicating that PTH1R is required for a 
normal development of the heart [8]. 
  Clinical data indicate that elevated PTH contributes to 
the progression of several cardiovascular diseases. Patients 
with end-stage renal diseases, which exhibit elevated plasma 
concentrations of PTH, develop severe left ventricular hyper-
trophy. Furthermore, cardiovascular diseases are the leading 
cause of mortality in end-stage renal disease patients [9, 10]. 
Moreover, parathyroidectomy in patients with extremely 
high serum PTH levels and accelerated left ventricular mass 
results in a marked reduction of both PTH levels and left 
ventricular mass [11, 12]. PTH is also an independent pre-Effect of Intermittent Versus Continuous Parathyroid Hormone  The Open Cardiovascular Medicine Journal, 2010, Volume 4    111 
dictor of left ventricular mass by high estimated with M-
mode echocardiography in males older than 59 years and 
females younger than 60 years [13]. This effect is only seen 
when PTH is substantially elevated. 
  These clinical data are supported by in vitro studies that 
demonstrate a direct hypertrophic effect of PTH on isolated 
adult ventricular cardiomyocytes [14]. Moreover, PTH in-
creases beating frequency and Ca
2+ influx of cardiomyocytes 
[15, 16]. 
  In this study, we aimed to investigate the effect of inter-
mittent and continuous administration of PTH on blood pres-
sure, heart rate and development of heart hypertrophy and 
fibrosis in rats.  
2. METHODS 
2.1. Animal Model 
  Male Wistar rats 200–220 g were anesthetized by subcu-
taneous injection of Hypnorm/ Dormicum for a chronic 
catheterization procedure. Through the right internal carotid 
artery, one catheter (medical-grade Tygon tubing) was 
placed with its tip in the ascending aorta. The catheter was 
subsequently filled with a solution containing 0.5 ml glucose 
(500 g/l), heparin (100 IU) and streptokinase (5000 IU) and 
plugged
  with a nylon pin. Each catheter was immediately 
externalized through the neck skin region and secured by a 
polyester felt disk placed in the subcutis [17]. 
  Following the catheter implantation, the rats were housed 
individually (12 h light/ 12 h dark) with unlimited amounts 
of standard rat chow and tap water. Post-operatively, the rats 
were allowed to recover for at least 5 days in order to obtain 
their pre-operative weight. 
  Before entering the test program both test and control 
animals base-line blood pressure (BP) were measured using 
pressure
  transducers (Baxter Corp) connected to the right 
arterial catheter.
 Hart rate (HR) was derived from the arterial 
pressure signal. Tracings of the variables were displayed on 
a Watanabe linear recorder (Watanabe Instruments Corp., 
Japan [17]). 
  Animals were conscious and unrestrained throughout 
measurement of BP and HR. After baseline hæmodynamics 
were measured, PTH (1-34) was administered either con-
tinuous or pulsative during 2 weeks. Pulsative administra-
tions were performed once daily (30 g/kg/day) or twice 
daily (15 g/kg/day) as a subcutaneous bolus injections of 
PTH. Continuous administrations were performed using an 
osmotic minipump
 (Alza Corp, 2002 12 l/d was placed sub-
cutaneously delivering PTH (6 g/day) or placebo (acetic 
acid (vehicle)) at a constant rate of 12 l/d throughout the 
study period. 
  At the end of the study period the BP and HR of the ani-
mals were measured and recorded. Subsequently, all animals 
were sacrificed and blood samples were drawn from aorta 
and analysed on a Ciba Corning 634 Ca++ /pH Analyzer® , 
ion-selective electrodes to estimate the serum Ca
2+  levels 
(ionic calcium) [18] . Hearts were removed and weighed 
(total weight, left and right ventricle weight) and snap frozen 
in liquate nitrogen. The length of the femur was measured 
before being snap frozen in liquid nitrogen.  
  All experiments conform with the Guide for the Care and 
Use of Laboratory Animals published by the US National 
Institutes of Health NIH publication no. 85-23, revised 1996. 
2.2. Quantification with Real-Time PCR 
  Total RNA was isolated from 10-30 mg of heart tissue 
(left ventricle) with RNeasy Fibrous Tissue Kit (Qiagen) 
after homogenization with a Mixer Mill 300MM (Retsch, 
Haan, Germany). RNA purity and concentration were deter-
mined by A260 and A280 measurement. First-strand cDNA 
was synthesised from 1μg of total RNA using Omniscript RT 
kit (Qiagen). 
  Quantitative real-time PCR analyses were performed 
with the Rotor-Gene 3000 (Corbett Research, Mortlake, 
Australia) and Quantitect SYBR Green PCR Kit (Qiagen) as 
described previously [19]. The primers were: 
  GAPDH, forward: 5'- GTC GGT GTG AAC GGA TTT 
G -3' 
  GAPDH, reverse: 5'- CTT CCC GTG GGT AGA GTC 
AT -3' 
  Collagen-I, forward: 5'- AGC TTC ACC CTT AGC ACC 
AG -3' 
  Collagen-I, reverse: 5'- GTG GTA ACG ATG GTG CTG 
TC -3' 
  Collagen-III, forward: 5'- ACC AGG GTC GCC ATT 
TCT -3' 
  Collagen-III, reverse: 5'- GCC TTC TAC ACC TGC 
TCC TG -3' 
  Fibronectin, forward: 5'- GTT TTG ACA ACG GGA 
AGC AT -3' 
  Fibronectin, reverse: 5'- TCT TCA GGT TCA GGC TTG 
CT -3' 
  ANP, forward: 5’- CCG GTA CCG AAG ATA ACA G-
3’ 
  ANP, reverse: 5’- CTC CAG GAG GGT ATT CAC C-3’ 
  The specificity of each set of primers was ensured by 
1.4% agarose gel analysis and DNA sequence analysis 
(GATC Biotech, Konstanz, Germany). All mRNAs were 
quantified in duplicates and the results were normalized to 
the content of GAPDH within the same sample.  
2.3. Calculations and Statistics 
  MAP was estimated, in mmHg, as diastolic pressure plus 
(systolic
  minus diastolic pressure) divided by 3. All data 
were analyzed with GraphPad Prism using two-tailed un-
paired t-test. P < 0.05 was considered significant. n= number 
of animals 
3. RESULTS 
3.1. Continuous Administration of PTH  
  A continuous infusion of PTH or vehicle was given for a 
period of 14 days. By end of the treatment, PTH animals 
were compared to vehicle treated animals (controls). PTH in 
the mini pumps was released as reflected in the serum ion-
ized calcium level, as serum Ca
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the PTH treated animals compared with controls (p=0.02) 
(Fig.  1a). No significant difference was found in body 
weight, lung weight, tibia length, or BP (data not shown). 
Moreover, no visible signs of heart hypertrophy were   
observed, as measured by the left ventricle mass (Fig. 1b). 
However, mRNA level of a hypertrophic marker gene, atrial 
natriuretic peptide (ANP), was significantly increased in the 
PTH treated animals (p=0.04) (Fig. 2a). No changes in 
mRNA levels of fibrotic gene markers, collagen 1, collagen 
3 and fibronectin were observed (Figs. 2b-d). In the end   
of the experiment, heart rate tended to be lower in the   
PTH treated animals (no significance, p=0.08) (Fig. 3a). No 
difference was observed before the experiment (Fig. 3b). 
Excluding 2 clear outliers in the control group, the change in 
the heart rate from baseline to end of the experiment (delta 
heart rate) was significantly lower in the PTH animals 
(p=0.01) (Fig. 3c).  
3.2. Intermittent Administration of PTH  
  Animals injected with PTH did not differ in body weight, 
lung weight or tibia length from animals injected with vehi-
cle (data not shown). Serum Ca
2+ tended to be higher in the 
PTH injected animals, however not significantly (Fig. 4a). 
No changes in the left ventricle mass or ANP, collagen 3 and 
fibronectin mRNA levels were observed in the PTH treated 
 
 
 
 
 
 
 
 
Fig. (1). Effect of continuous administration of PTH on: (a) Serum Ca
2+ level. (b) Left ventricle mass. Each point represents a value from an 
individual rat. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Left ventricular expression of mRNAs for atrial natriuretic peptide (ANP) (a), Collagen1 (b), Collagen3 (c) and Fibronectin (d) in 
rats treated with continuous administration of PTH. Each point represents a value from an individual rat. Effect of Intermittent Versus Continuous Parathyroid Hormone  The Open Cardiovascular Medicine Journal, 2010, Volume 4    113 
group (Figs 4b,  5a, 5c, and 5d). Expression of collagen1 
mRNA tended to be lower in the PTH injected animals, 
however not significantly (Fig. 5b). 
3.3. Continuous Versus Intermittent Administration of 
PTH 
  We compared animals treated with continuous and inter-
mittent administration of PTH. No significant difference in 
body weight or left ventricle mass was observed (Figs 6a and 
6b). Serum calcium tended to be higher in animals treated 
with continuous administration of PTH, however not signifi-
cantly (Fig. 6c). Moreover, expression of collagen 1 mRNA 
was significantly higher in continuously treated animals 
(p=0.03) (Fig. 7).  
4. DISCUSSION 
  PTH is the most important regulator of calcium homeo-
stasis and a key factor in the control of bone modelling. In-
terestingly, PTH has opposite effects on bone, depending 
upon the mode of application [5]. Brief daily exposures   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Effect of continuous administration of PTH on heart rate (BMP). (a) Heart rate by the end of the experiment. (b) Heart rate in  
the beginning of the experiment. (c) Delta heart rate (excluding 2 outliners from the control group). Each point represents a value from an 
individual rat. 
 
 
 
 
 
 
 
 
Fig. (4). Effect of intermittent administration of PTH on: (a) Serum Ca
2+ level. (b) Left ventricle mass. Each point represents a value from an 
individual rat. 114    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Smajilovic et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Left ventricular expression of mRNAs for atrial natriuretic peptide (ANP) (a), Collagen1 (b), Collagen3 (c) and Fibronectin (d) in 
rats treated with intermittent administration of PTH. Each point represents a value from an individual rat. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Effect of continuous versus intermittent administration of PTH on: (a) Body weight. (b) Left ventricle mass. (c) Serum Ca
2+ level. 
Each point represents a value from an individual rat. Effect of Intermittent Versus Continuous Parathyroid Hormone  The Open Cardiovascular Medicine Journal, 2010, Volume 4    115 
 
result in anabolic effects, while continuously administration 
at a sustained level has catabolic effects. Daily injections of 
PTH are used as a novel and promising anabolic treatment 
for osteoporosis [4]. 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Effect of continuous versus intermittent administration of 
PTH on left ventricular expression of mRNA for Collagen1. Each 
point represents a value from an individual rat. 
  Although PTH acts primarely on bone and kidney cells, it 
is well known that cardiovascular cells are target cells for 
PTH [20]. PTH increases calcium influx in cardiomyocytes 
but decreases calcium influx in smooth muscle cells [20]. 
Moreover, PTH exerts a direct hypertrophic effect on   
cardiomyocytes and increases their beating frequency [14-
16].  
  In this study, we examined effects of PTH on BP, heart 
rate and left ventricle mass in rats.  
  The effect of PTH on BP is complex. It causes acute 
vasodilation and lowers BP in rats [21]. However, infusion 
of human PTH (1-34) in healthy volunteers causes an acute 
modest increase in BP [22]. Recently, Zaruba et al. observed 
a decrease in BP after PTH injections in mice [23]. This 
study did not include a control (vehicle treated) group, and 
can therefore not exclude that the decrease in BP occurred 
spontaneously over time and is not an effect of PTH.  
  It is important to keep in mind the possibility of species-
related differences and of different short-term versus long-
term BP effects of PTH. Although PTH causes acute de-
crease in BP in rats, it has been proposed that this acute BP-
lowering effect might be suppressed in the long run by an 
elevation of the BP that results from cellular calcium loading 
[24]. Accordingly, continuous administration of PTH did not 
have any effect on BP in our study.  
  PTH has previously been demonstrated to induce an in-
crease in heart rate both in cultured cardiomyocytes [15, 16] 
and in isolated perfused hearts [25]. Moreover, intermittent 
administration of PTH in rats has also been reported to pro-
duce an increase in heart rate [26]. However, in the present 
study, continuous PTH administration led to a slowing of the 
heart rate. Interestingly, it has previously been demonstrated 
that an overexpression of the PTH1R in rats decreases heart 
rate [27]. The mechanisms underlying this negative chro-
notropic effect are not clear.  
  Our data, together with previous studies, suggest that 
intermittent administration of PTH leads to an acute increase 
in heart rate, while continuous administration of PTH   
decreases heart rate.  
  PTH has previously been demonstrated to directly induce 
hypertrophy of isolated rat cardiomyocytes [14]. In addition, 
70% of patients with end-stage renal disease, which exhibit 
elevated plasma PTH levels, suffer from severe left ventricu-
lar hypertrophy [10, 28]. Therefore, we investigated the ef-
fect of both intermittent and continuous administration of 
PTH on left ventricle mass. Neither treatment led to devel-
opment of hypertrophy in our study, measured by left ventri-
cle mass. However, expression of a hypertrophic marker 
gene, atrial natriuretic peptide (ANP), was significantly in-
creased in animals treated with continuous administration of 
PTH compared with controls, suggesting that hypertrophic 
process appeared to begin. The lack of visible signs of a 
hypertrophic heart (increase in left ventricle mass) could be 
caused by a too short exposure compared with the human 
observations. 
  We also investigated mRNA expression of fibrotic gene 
markers, collagen 1, collagen 3 and fibronectin. Neither 
treatment led to significant changes in expression of the fi-
brotic gene markers. However, level of collagen 1 mRNA 
tended to be lower in animals treated with intermittent ad-
ministration of PTH. 
  In summary, our data demonstrate, to our knowledge   
for the first time, a decrease in heart rate upon continuous 
administration of PTH in rats. No changes in BP were   
observed. Moreover, neither intermittent nor continuous   
administration of PTH induced ventricular hypertrophy or a 
fibrotic process in the timeframe of this study.  
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